{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:11:51Z","timestamp":1791263511198,"version":"4.1.0"},"reference-count":99,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,12,1]]},"abstract":"<jats:title>Learning Objectives<\/jats:title><jats:p>After completing this course, the reader will be able to: List the most frequent genetic abnormalities involved in RCC and explain how they lead to abnormal response to hypoxia, cell survival, and angiogenesis.Interpret the current literature concerning the treatment of RCC, and correlate therapeutic agents with their targets and underlying biological processes that drive the disease.Identify the limitations of current agents used in the treatment of RCC and the challenges that need to be overcome in developing therapies to improve the outcome of patients with advanced disease.<\/jats:p><jats:p>Access and take the CME test online and receive 1 AMA PRA Category 1 Credit\u2122 at CME.TheOncologist.com<\/jats:p>","DOI":"10.1634\/theoncologist.12-12-1404","type":"journal-article","created":{"date-parts":[[2007,12,28]],"date-time":"2007-12-28T23:48:38Z","timestamp":1198885718000},"page":"1404-1415","source":"Crossref","is-referenced-by-count":98,"title":["Renal Cell Carcinoma: New Developments in Molecular Biology and Potential for Targeted Therapies"],"prefix":"10.1093","volume":"12","author":[{"given":"Luciano J.","family":"Costa","sequence":"first","affiliation":[{"name":"a University of Colorado Health Sciences Center, Denver, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry A.","family":"Drabkin","sequence":"additional","affiliation":[{"name":"b Medical University of South Carolina, Division of Hematology-Oncology, Charleston, South Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2007,12,1]]},"reference":[{"key":"2021122209031122600_R1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3322\/canjclin.56.2.106","article-title":"Cancer statistics, 2006","volume":"56","author":"Jemal","year":"2006","journal-title":"CA Cancer J Clin"},{"key":"2021122209031122600_R2","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1081\/CNV-200055962","article-title":"Lifestyle factors, exposures, genetic susceptibility, and renal cell cancer risk: A review","volume":"23","author":"Moore","year":"2005","journal-title":"Cancer Invest"},{"key":"2021122209031122600_R3","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.bbrc.2005.08.165","article-title":"The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing","volume":"338","author":"Kaelin","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"2021122209031122600_R4","doi-asserted-by":"crossref","first-page":"19410","DOI":"10.1074\/jbc.M501778200","article-title":"Differential gene regulation of StarD4 and StarD5 cholesterol transfer proteins. Activation of StarD4 by sterol regulatory element-binding protein-2 and StarD5 by endoplasmic reticulum stress","volume":"280","author":"Soccio","year":"2005","journal-title":"J Biol Chem"},{"key":"2021122209031122600_R5","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2004.05.061","article-title":"Role of VHL gene mutation in human cancer","volume":"22","author":"Kim","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122209031122600_R6","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/jnci\/94.20.1569","article-title":"VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma","volume":"94","author":"Yao","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"2021122209031122600_R7","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1097-2765(00)80096-9","article-title":"The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix","volume":"1","author":"Ohh","year":"1998","journal-title":"Mol Cell"},{"key":"2021122209031122600_R8","first-page":"2929","article-title":"Role of the von Hippel-Lindau tumor suppressor gene in the formation of beta1-integrin fibrillar adhesions","volume":"62","author":"Esteban-Barragan","year":"2002","journal-title":"Cancer Res"},{"key":"2021122209031122600_R9","doi-asserted-by":"crossref","first-page":"43611","DOI":"10.1074\/jbc.M107880200","article-title":"The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C","volume":"276","author":"Okuda","year":"2001","journal-title":"J Biol Chem"},{"key":"2021122209031122600_R10","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1681\/ASN.2006020181","article-title":"Formation of primary cilia in the renal epithelium is regulated by the von Hippel-Lindau tumor suppressor protein","volume":"17","author":"Esteban","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2021122209031122600_R11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.molcel.2006.04.006","article-title":"p53 stabilization and transactivation by a von Hippel-Lindau protein","volume":"22","author":"Roe","year":"2006","journal-title":"Mol Cell"},{"key":"2021122209031122600_R12","doi-asserted-by":"crossref","first-page":"38458","DOI":"10.1074\/jbc.M406026200","article-title":"Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor","volume":"279","author":"Appelhoff","year":"2004","journal-title":"J Biol Chem"},{"key":"2021122209031122600_R13","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.cmet.2005.05.003","article-title":"Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation","volume":"1","author":"Mansfield","year":"2005","journal-title":"Cell Metab"},{"key":"2021122209031122600_R14","doi-asserted-by":"crossref","first-page":"25130","DOI":"10.1074\/jbc.M001914200","article-title":"Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1alpha during hypoxia: A mechanism of O2 sensing","volume":"275","author":"Chandel","year":"2000","journal-title":"J Biol Chem"},{"key":"2021122209031122600_R15","doi-asserted-by":"crossref","first-page":"L922","DOI":"10.1152\/ajplung.00014.2002","article-title":"Hypoxic but not anoxic stabilization of HIF-1alpha requires mitochondrial reactive oxygen species","volume":"283","author":"Schroedl","year":"2002","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2021122209031122600_R16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1086\/381054","article-title":"Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma","volume":"74","author":"Vanharanta","year":"2004","journal-title":"Am J Hum Genet"},{"key":"2021122209031122600_R17","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ng849","article-title":"Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer","volume":"30","author":"Tomlinson","year":"2002","journal-title":"Nat Genet"},{"key":"2021122209031122600_R18","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/ng0597-68","article-title":"Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas","volume":"16","author":"Schmidt","year":"1997","journal-title":"Nat Genet"},{"key":"2021122209031122600_R19","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/ng0195-70","article-title":"A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer","volume":"9","author":"Kobayashi","year":"1995","journal-title":"Nat Genet"},{"key":"2021122209031122600_R20","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1535-6108(02)00071-5","article-title":"HIF activation identifies early lesions in VHL kidneys: Evidence for site-specific tumor suppressor function in the nephron","volume":"1","author":"Mandriota","year":"2002","journal-title":"Cancer Cell"},{"key":"2021122209031122600_R21","doi-asserted-by":"crossref","first-page":"E83","DOI":"10.1371\/journal.pbio.0000083","article-title":"Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth","volume":"1","author":"Kondo","year":"2003","journal-title":"PLoS Biol"},{"key":"2021122209031122600_R22","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1038\/sj.onc.1205437","article-title":"The TRC8 hereditary kidney cancer gene suppresses growth and functions with VHL in a common pathway","volume":"21","author":"Gemmill","year":"2002","journal-title":"Oncogene"},{"key":"2021122209031122600_R23","doi-asserted-by":"crossref","first-page":"9572","DOI":"10.1073\/pnas.95.16.9572","article-title":"The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a patched-related gene, TRC8","volume":"95","author":"Gemmill","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122209031122600_R24","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/gcc.20466","article-title":"A constitutional balanced t(3;8)(p14;q24.1) translocation results in disruption of the TRC8 gene and predisposition to clear cell renal cell carcinoma","volume":"46","author":"Poland","year":"2007","journal-title":"Genes Chromosomes Cancer"},{"key":"2021122209031122600_R25","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1038\/sj.onc.1210017","article-title":"RING-dependent tumor suppression and G2\/M arrest induced by the TRC8 hereditary kidney cancer gene","volume":"26","author":"Brauweiler","year":"2007","journal-title":"Oncogene"},{"key":"2021122209031122600_R26","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1128\/MCB.26.7.2817-2831.2006","article-title":"Sterol regulatory element binding protein is a principal regulator of anaerobic gene expression in fission yeast","volume":"26","author":"Todd","year":"2006","journal-title":"Mol Cell Biol"},{"key":"2021122209031122600_R27","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.cell.2005.01.012","article-title":"SREBP pathway responds to sterols and functions as an oxygen sensor in fission yeast","volume":"120","author":"Hughes","year":"2005","journal-title":"Cell"},{"key":"2021122209031122600_R28","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/01.ju.0000110610.61545.ae","article-title":"Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis","volume":"171","author":"Flanigan","year":"2004","journal-title":"J Urol"},{"key":"2021122209031122600_R29","first-page":"42","article-title":"Chemotherapy for advanced renal-cell carcinoma: 1983\u20131993","volume":"22","author":"Yagoda","year":"1995","journal-title":"Semin Oncol"},{"key":"2021122209031122600_R30","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/sj.bjc.6602209","article-title":"Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma","volume":"91","author":"Waters","year":"2004","journal-title":"Br J Cancer"},{"key":"2021122209031122600_R31","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/cncr.20541","article-title":"Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma","volume":"101","author":"Nanus","year":"2004","journal-title":"Cancer"},{"key":"2021122209031122600_R32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0090-4295(82)90356-9","article-title":"Spontaneous regression of metastatic renal cell carcinoma","volume":"20","author":"Snow","year":"1982","journal-title":"Urology"},{"key":"2021122209031122600_R33","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/jnci\/85.8.622","article-title":"Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer","volume":"85","author":"Rosenberg","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"2021122209031122600_R34","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J Clin Oncol"},{"key":"2021122209031122600_R35","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JCO.2005.03.206","article-title":"Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma","volume":"23","author":"McDermott","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122209031122600_R36","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1200\/JCO.2003.02.122","article-title":"Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer","volume":"21","author":"Yang","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122209031122600_R37","first-page":"87","article-title":"Role of interferons in the therapy of metastatic renal cell carcinoma","volume-title":"Urology","author":"Quesada","year":"1989"},{"key":"2021122209031122600_R38","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0140-6736(98)03544-2","article-title":"Interferon-alpha and survival in metastatic renal carcinoma: Early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"2021122209031122600_R39","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1056\/NEJM200009143431101","article-title":"Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation","volume":"343","author":"Childs","year":"2000","journal-title":"N Engl J Med"},{"key":"2021122209031122600_R40","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.bbmt.2006.03.011","article-title":"Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: A CALGB intergroup phase II study","volume":"12","author":"Rini","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"2021122209031122600_R41","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1200\/JCO.2005.01.186","article-title":"Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma","volume":"23","author":"Rini","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122209031122600_R42","first-page":"4593","article-title":"Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Res"},{"key":"2021122209031122600_R43","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2001.19.3.843","article-title":"Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122209031122600_R44","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1200\/JCO.2001.19.3.851","article-title":"Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data","volume":"19","author":"Margolin","year":"2001","journal-title":"J Clin Oncol"},{"key":"2021122209031122600_R45","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med"},{"key":"2021122209031122600_R46","doi-asserted-by":"crossref","first-page":"7889","DOI":"10.1200\/JCO.2005.01.8234","article-title":"Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib","volume":"23","author":"Hainsworth","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122209031122600_R47","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1200\/jco.2006.24.18_suppl.4523","article-title":"Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC)","volume":"24","author":"Bukowski","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122209031122600_R48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1200\/jco.2007.25.18_suppl.3","article-title":"A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab\/interferon-\u03b12a vs placebo\/interferon- \u03b12a as first-line therapy in metastatic renal cell carcinoma","volume":"25","author":"Escudier","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122209031122600_R49","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"2021122209031122600_R50","doi-asserted-by":"crossref","first-page":"6388S","DOI":"10.1158\/1078-0432.CCR-040028","article-title":"Kinase inhibition with BAY 43-9006 in renal cell carcinoma","volume":"10","author":"Ahmad","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2021122209031122600_R51","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"2021122209031122600_R52","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1634\/theoncologist.12-4-426","article-title":"Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors","volume":"12","author":"Strumberg","year":"2007","journal-title":"The Oncologist"},{"key":"2021122209031122600_R53","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma","volume":"24","author":"Ratain","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122209031122600_R54","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2004.06.132","article-title":"Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma","volume":"22","author":"Motzer","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122209031122600_R55","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122209031122600_R56","doi-asserted-by":"crossref","first-page":"5025","DOI":"10.1200\/jco.2007.25.18_suppl.5025","article-title":"Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results","volume":"25","author":"Szczylik","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122209031122600_R57","doi-asserted-by":"crossref","first-page":"5096","DOI":"10.1200\/jco.2007.25.18_suppl.5096","article-title":"The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Long-term outcomes in first-line patients (pts)","volume":"25","author":"Ryan","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122209031122600_R58","doi-asserted-by":"crossref","first-page":"5026","DOI":"10.1200\/jco.2007.25.18_suppl.5026","article-title":"A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC)","volume":"25","author":"Amato","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122209031122600_R59","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1200\/jco.2006.24.18_suppl.4525","article-title":"Sorafenib plus interferon-\u03b12b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412","volume":"24","author":"Ryan","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122209031122600_R60","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2021122209031122600_R61","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","article-title":"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122209031122600_R62","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","article-title":"Sunitinib in patients with metastatic renal cell carcinoma","volume":"295","author":"Motzer","year":"2006","journal-title":"JAMA"},{"key":"2021122209031122600_R63","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122209031122600_R64","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1200\/jco.2007.25.18_suppl.5038","article-title":"Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients","volume":"25","author":"Sablin","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122209031122600_R65","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1200\/jco.2007.25.18_suppl.5031","article-title":"Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT)","volume":"25","author":"Hutson","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122209031122600_R66","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1200\/JCO.2005.04.192","article-title":"Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results","volume":"23","author":"Rugo","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122209031122600_R67","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1200\/jco.2007.25.18_suppl.5032","article-title":"Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib","volume":"25","author":"Rini","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122209031122600_R68","doi-asserted-by":"crossref","first-page":"5048","DOI":"10.1200\/jco.2007.25.18_suppl.5048","article-title":"Thyroid function test (TFT) abnormalities in patients (pts) with metastatic renal cell carcinoma (RCC) treated with sorafenib","volume":"25","author":"Tamaskar","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122209031122600_R69","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-145-9-200611070-00008","article-title":"Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors","volume":"145","author":"Desai","year":"2006","journal-title":"Ann Intern Med"},{"key":"2021122209031122600_R70","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.cell.2007.06.054","article-title":"Autocrine VEGF signaling is required for vascular homeostasis","volume":"130","author":"Lee","year":"2007","journal-title":"Cell"},{"key":"2021122209031122600_R71","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1023\/A:1022943419011","article-title":"Translational control and metastatic progression: Enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs","volume":"20","author":"Graff","year":"2003","journal-title":"Clin Exp Metastasis"},{"key":"2021122209031122600_R72","first-page":"5645","article-title":"Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors","volume":"62","author":"Kenerson","year":"2002","journal-title":"Cancer Res"},{"key":"2021122209031122600_R73","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/1097-0215(200002)9999:9999<::AID-IJC1034>3.0.CO;2-S","article-title":"PTEN\/MMAC1\/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines","volume":"91","author":"Kondo","year":"2001","journal-title":"Int J Cancer"},{"key":"2021122209031122600_R74","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1074\/jbc.270.2.815","article-title":"Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells","volume":"270","author":"Sabers","year":"1995","journal-title":"J Biol Chem"},{"key":"2021122209031122600_R75","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/jnci\/93.20.1517","article-title":"Rapamycin's resurrection: A new way to target the cancer cell cycle","volume":"93","author":"Garber","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"2021122209031122600_R76","doi-asserted-by":"crossref","first-page":"6680","DOI":"10.1038\/sj.onc.1204091","article-title":"The rapamycin-sensitive signal transduction pathway as a target for cancer therapy","volume":"19","author":"Hidalgo","year":"2000","journal-title":"Oncogene"},{"key":"2021122209031122600_R77","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nm0202-128","article-title":"Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor","volume":"8","author":"Guba","year":"2002","journal-title":"Nat Med"},{"key":"2021122209031122600_R78","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1200\/JCO.2004.08.116","article-title":"Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer","volume":"22","author":"Raymond","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122209031122600_R79","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122209031122600_R80","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122209031122600_R81","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1200\/jco.2007.25.18_suppl.5107","article-title":"A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC)","volume":"25","author":"Jac","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122209031122600_R82","first-page":"3384","article-title":"Tumor-inhibitory antibodies to HER-2\/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2","volume":"60","author":"Klapper","year":"2000","journal-title":"Cancer Res"},{"key":"2021122209031122600_R83","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1093\/emboj\/19.13.3159","article-title":"The ErbB signaling network: Receptor heterodimerization in development and cancer","volume":"19","author":"Olayioye","year":"2000","journal-title":"EMBO J"},{"key":"2021122209031122600_R84","first-page":"6972","article-title":"Expression of transforming growth factor alpha in normal human adult kidney and enhanced expression of transforming growth factors alpha and beta 1 in renal cell carcinoma","volume":"49","author":"Gomella","year":"1989","journal-title":"Cancer Res"},{"key":"2021122209031122600_R85","first-page":"538","article-title":"Effects of transforming growth factor-beta, transforming growth factor-alpha, and other growth factors on renal proximal tubule cells","volume":"64","author":"Humes","year":"1991","journal-title":"Lab Invest"},{"key":"2021122209031122600_R86","first-page":"913","article-title":"Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: Correlation with metastatic behavior and prognosis","volume":"1","author":"Uhlman","year":"1995","journal-title":"Clin Cancer Res"},{"key":"2021122209031122600_R87","first-page":"1387","article-title":"Role of transforming growth factor-alpha in von Hippel\u2013Lindau (VHL)(-\/-) clear cell renal carcinoma cell proliferation: A possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis","volume":"98","author":"de Paulsen","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122209031122600_R88","first-page":"226","article-title":"Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor","volume":"58","author":"Knebelmann","year":"1998","journal-title":"Cancer Res"},{"key":"2021122209031122600_R89","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.1158\/1078-0432.CCR-04-0310","article-title":"A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renalcell carcinoma","volume":"10","author":"Dawson","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2021122209031122600_R90","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1200\/jco.2006.24.18_suppl.4502","article-title":"Efficacy of lapatinib in patients with high tumor EGFR expression: Results of a phase III trial in advanced renal cell carcinoma (RCC)","volume":"24","author":"Ravaud","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122209031122600_R91","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1038\/sj.onc.1204525","article-title":"Constitutive activation of nuclear factor-kappaB prevents TRAIL-induced apoptosis in renal cancer cells","volume":"20","author":"Oya","year":"2001","journal-title":"Oncogene"},{"key":"2021122209031122600_R92","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1159\/000052489","article-title":"Interferon-alpha suppresses the antiapoptotic effect of NF-kB and sensitizes renal cell carcinoma cells in vitro to chemotherapeutic drugs","volume":"39","author":"Steiner","year":"2001","journal-title":"Eur Urol"},{"key":"2021122209031122600_R93","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1158\/1535-7163.727.3.6","article-title":"Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent","volume":"3","author":"An","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"2021122209031122600_R94","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1200\/JCO.2004.10.155","article-title":"Phase II trial of bortezomib for patients with advanced renal cell carcinoma","volume":"22","author":"Kondagunta","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122209031122600_R95","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.2004.07.165","article-title":"Phase II trial of PS-341 in patients with renal cell cancer: A University of Chicago phase II consortium study","volume":"22","author":"Davis","year":"2004","journal-title":"J Clin Oncol"},{"key":"2021122209031122600_R96","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1073\/pnas.0307708100","article-title":"Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1","volume":"101","author":"Gui","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122209031122600_R97","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1158\/1078-0432.CCR-06-1261","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: Effects on gene expression and growth of glioma cells in vitro and in vivo","volume":"13","author":"Yin","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2021122209031122600_R98","doi-asserted-by":"crossref","first-page":"20436","DOI":"10.1074\/jbc.M000202200","article-title":"Histone deacetylases specifically down-regulate p53-dependent gene activation","volume":"275","author":"Juan","year":"2000","journal-title":"J Biol Chem"},{"key":"2021122209031122600_R99","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.12-12-1404","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.12-12-1404","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/12\/12\/1404\/41835634\/oncolo_12_12_1404.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/12\/12\/1404\/41835634\/oncolo_12_12_1404.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T14:00:27Z","timestamp":1684159227000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/12\/12\/1404\/6398759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,1]]},"references-count":99,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2007,12,1]]},"published-print":{"date-parts":[[2007,12,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.12-12-1404","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2007,12,1]]},"published":{"date-parts":[[2007,12,1]]}}}